• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Rockwell Medical Inc.

    10/8/24 9:24:48 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RMTI alert in real time by email
    S-8 1 tm2425744d3_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on October 8, 2024

    Registration No. 333-             

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

     

    ROCKWELL MEDICAL, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   38-3317208

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

     

    30142 Wixom Road
    Wixom, Michigan 48393

    (248) 960-9009

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Non-Plan Inducement Stock Option

    (Full title of the plans)

     

     

    Mark Strobeck, Ph.D.

    President and Chief Executive Officer 

    Rockwell Medical, Inc.

    30142 Wixom Road

    Wixom, Michigan 48393

    (248) 960-9009

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

    Ryan A. Murr
    Gibson, Dunn & Crutcher LLP
    One Embarcadero Center, Suite 2600
    San Francisco, CA 94111
    (415) 393-8373
    ​ Megan C. Timmins
    EVP, CLO and Secretary
    Rockwell Medical, Inc.
    30142 S. Wixom Road
    Wixom, Michigan 48393
    (248) 960-9009

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a small reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ¨   Accelerated filer   ¨
    Non-accelerated filer   x   Smaller reporting company   x
            Emerging growth company   ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed to register 75,000 shares of Rockwell Medical, Inc. (the “Company” or the “Registrant”) common stock, par value $0.0001 per share, issuable under a previously announced stand-alone inducement award.

     

    Part I

     

    Information Required in the Section 10(a) Prospectus

     

    The information required by Item 1 and Item 2 of Part I of Form S-8 is omitted from this filing in accordance with Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the introductory note to Part I of Form S-8.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference

     

    The following documents filed by the Company with the Securities and Exchange Commission (the “Commission”) are incorporated by reference into this Registration Statement:

     

      1. The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on March 21, 2024, including the information specifically incorporated by reference therein from our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 15, 2024;

     

      2. The Company’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2024, and June 30, 2024, filed with the SEC on May 14, 2024, and August 8, 2024, respectively;

     

      3. The Company’s Current Reports on Form 8-K, filed with the SEC on January 8, 2024, May 23, 2024, and July 15, 2024; and

     

      4. The Company’s description of its common stock contained in our Registration Statement on Form 8-A filed with the SEC on January 23, 1998, as well as any subsequent amendments or reports filed for the purpose of updating such description.

     

    All reports or other documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold hereunder, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of filing such reports and documents. Notwithstanding the foregoing, unless specifically stated to the contrary in such filing, none of the information that the Registrant discloses under Items 2.02 or 7.01 of any Current Report on Form 8-K that it may from time to time furnish to the Commission will be incorporated by reference into, or otherwise be included in or deemed to be a part of, this Registration Statement.

     

    Any statement contained in a document incorporated by reference into this Registration Statement shall be deemed to be modified or superseded for purposes hereof to the extent that a statement contained herein (or in any other subsequently filed document which also is or is deemed incorporated herein) modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed to constitute a part hereof, except as so modified or superseded.

     

     

     

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    Item 6. Indemnification of Directors and Officers.

     

    The Company is a Delaware corporation. Section 145(a) of the Delaware General Corporation Law, or the DGCL, provides that a Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, other than an action by or in the right of the corporation, by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.

     

    Section 145(b) of the DGCL provides that a Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that such person acted in any of the capacities set forth above, against expenses (including attorneys’ fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in, or not opposed to, the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation, unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine, upon application, that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the court shall deem proper.

     

    Further subsections of DGCL Section 145 provide that:

     

    (1)            to the extent a present or former director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (i) and (ii) of Section 145 or in the defense of any claim, issue or matter therein, such person shall be indemnified against expenses, including attorneys’ fees, actually and reasonably incurred by such person in connection therewith;

     

    (2)            the indemnification and advancement of expenses provided for pursuant to Section 145 shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise; and

     

     

     

     

    (3)            the corporation shall have the power to purchase and maintain insurance of behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person’s status as such, whether or not the corporation would have the power to indemnify such person against such liability under Section 145.

     

    As used in this Item 6, the term “proceeding” means any threatened, pending or completed action, suit or proceeding, whether or not by or in the right of the Company, and whether civil, criminal, administrative, investigative or otherwise.

     

    Section 145 of the DGCL makes provision for the indemnification of officers and directors in terms sufficiently broad to indemnify officers and directors of the Company under certain circumstances from liabilities (including reimbursement for expenses incurred) arising under the Securities Act. The Company’s organizational documents provide, in effect, that, to the fullest extent and under the circumstances permitted by Section 145 of the DGCL, the Company will indemnify any and all of its officers and directors. The Company has entered into indemnification agreements with its officers and directors. The Company may, in its discretion, similarly indemnify its employees and agents. The Company’s certificate of incorporation also relieves its directors from monetary damages to the Company or its stockholders for breach of such director’s fiduciary duty as a director to the fullest extent permitted by the DGCL. Under Section 102(b)(7) of the DGCL, a corporation may relieve its directors from personal liability to such corporation or its stockholders for monetary damages for any breach of their fiduciary duty as directors except (i) for a breach of the duty of loyalty, (ii) for failure to act in good faith, (iii) for intentional misconduct or knowing violation of law, (iv) for willful or negligent violations of certain provisions in the DGCL imposing certain requirements with respect to stock repurchases, redemptions and dividends or (v) for any transactions from which the director derived an improper personal benefit.

     

    The Company has purchased insurance policies that, within the limits and subject to the terms and conditions thereof, cover certain expenses and liabilities that may be incurred by directors and officers in connection with proceedings that may be brought against them as a result of an act or omission committed or suffered while acting as a director or officer of the Company

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits.

     

    Exhibit No.

     

    Description

       
    4.1   Certificate of Incorporation (filed with the SEC as Exhibit 3.3 to the Company’s Form 8-K filed on August 30, 2019)
         
    4.2   Certificate of Amendment to Certificate of Incorporation of Rockwell Medical, Inc. related to the Reverse Stock Split, dated May 12, 2022 (filed with the SEC as Exhibit 3.1 to the Company’s Form 8-K filed on May 13, 2022)
         
    4.3   Certificate of Designation of Preferences, Rights and Limitations of Series X Convertible Preferred Stock (filed with the SEC as Exhibit 3.1 to the Company’s Form 8-K filed on April 8, 2022)
         
    4.4   Amended and Restated Bylaws (filed with the SEC as Exhibit 3.1 to the Company's Form 10-Q filed on November 14, 2022)

     

     

     

     

    5.1*   Opinion of Gibson, Dunn & Crutcher LLP.
       
    23.1*   Consent of EisnerAmper LLP
         
    23.2*   Consent of Marcum LLP
         
    23.3*   Consent of Gibson, Dunn & Crutcher LLP (contained in Exhibit 5.1).
       
    24.1*   Power of Attorney (included in signature page to this Registration Statement)
         
    99.1   Form of Stock Option Agreement (2018 Long Term Incentive Plan) (filed with the SEC as Exhibit 10.2 to the Company’s Form 10-Q filed on November 14, 2022)
         
    107*   Calculation of Filing Fee Table

     

     

     

    *Filed herewith.

     

    Item 9. Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

     

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

     

    (iii)  To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the Registration Statement;

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and

     

     

     

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Wixom, State of Michigan, on this 8th day of October, 2024.

     

      ROCKWELL MEDICAL, INC.
         
      By: /s/ Mark Strobeck, Ph.D.
       

    Name: Mark Strobeck, Ph.D.

    Title: President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark Strobeck, Ph.D. as his or her attorney-in-fact, with full power of substitution, for him or her and in any and all capacities, to sign any and all amendments to this Registration Statement on this Form S-8 (including any post-effective amendments thereto) and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title Date
           

    /s/ Mark Strobeck, Ph.D.

      President, Chief Executive Officer and Director October 8, 2024
    Mark Strobeck, Ph.D.   (Principal Executive Officer and Principal Financial Officer)  
           
           

    /s/ Jesse Neri

      Senior Vice President, Finance and Principal Accounting Officer October 8, 2024
    Jesse Neri      
           

    /s/ John G. Cooper

      Director October 8, 2024
    John G. Cooper      
           

    /s/ Joan Lau, Ph.D.

      Director October 8, 2024
    Joan Lau, Ph.D.      
           

    /s/ Allen Nissenson, MD

      Director October 8, 2024
    Allen Nissenson, MD      
           

    /s/ Robert S. Radie

      Director October 8, 2024
    Robert S. Radie      
           

    /s/ Mark H. Ravich

      Director October 8, 2024
    Mark H. Ravich      
           

    /s/ Andrea Heslin Smiley

      Director October 8, 2024
    Andrea Heslin Smiley      

     

     

     

    Get the next $RMTI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RMTI

    DatePrice TargetRatingAnalyst
    11/14/2024$5.00Buy
    Rodman & Renshaw
    1/18/2022$5.00 → $3.00Buy
    HC Wainwright & Co.
    9/7/2021$5.50 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $RMTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rockwell Medical Named 'Great Place to Work' for Fourth Year in a Row

    Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company has been certified as a Great Place to Work® for the fourth year in a row. "Being recognized as a Great Place to Work for four consecutive years underscores that our people are the foundation of our success. Their dedication, passion, and commitment to our mission and values shape the culture that sets us apart," said Lesley Spriggs, Vice President of Human Resources at Rockwell Medical. "This achievement motivates us to continue fostering an environment

    2/12/26 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rockwell Medical Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Financial Results

    Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced preliminary unaudited financial results for the three months and twelve months ended December 31, 2025. "Our preliminary financial results for the fourth quarter 2025 reflect our unrelenting drive towards making Rockwell Medical a profitable company and positioning the Company for long-term stability and success," said Mark Strobeck, Ph.D., President and CEO of Rockwell Medical. "We saw a considerable increase in revenue, were cash flow positive, were Adjusted EBITDA pos

    1/20/26 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rockwell Medical Adds 30 New Customers in the West

    The Company generates multi-million dollars in revenue with new west coast customer base The Western U.S. now accounts for more than 10% of the Company's customer clinic footprint Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company has added 30 new customers in the western portion of the United States. "Over the past several months, the hemodialysis concentrates supply chain has experienced meaningful disruption, particularly in the western United States," said Mark Strobeck, Ph.D., President and CEO

    1/12/26 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RMTI
    SEC Filings

    View All

    Rockwell Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ROCKWELL MEDICAL, INC. (0001041024) (Filer)

    1/20/26 6:32:02 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rockwell Medical Inc. filed SEC Form 8-K: Other Events

    8-K - ROCKWELL MEDICAL, INC. (0001041024) (Filer)

    1/5/26 6:33:06 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rockwell Medical Inc. filed SEC Form 8-K: Leadership Update

    8-K - ROCKWELL MEDICAL, INC. (0001041024) (Filer)

    11/18/25 7:30:30 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RMTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Rockwell Medical with a new price target

    Rodman & Renshaw initiated coverage of Rockwell Medical with a rating of Buy and set a new price target of $5.00

    11/14/24 7:56:29 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Rockwell Medical with a new price target

    HC Wainwright & Co. reiterated coverage of Rockwell Medical with a rating of Buy and set a new price target of $3.00 from $5.00 previously

    1/18/22 10:00:06 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Rockwell Medical with a new price target

    HC Wainwright & Co. reiterated coverage of Rockwell Medical with a rating of Buy and set a new price target of $5.00 from $5.50 previously

    9/7/21 6:17:47 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RMTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $RMTI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Hunter Heather sold $2,396 worth of shares (2,868 units at $0.84), decreasing direct ownership by 2% to 132,523 units (SEC Form 4)

    4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

    1/5/26 4:15:59 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP and CFO Neri Jesse sold $740 worth of shares (886 units at $0.84), decreasing direct ownership by 0.70% to 124,842 units (SEC Form 4)

    4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

    1/5/26 4:13:26 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Dawson Joseph H was granted 25,000 shares (SEC Form 4)

    4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

    11/20/25 7:37:17 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Irrevocable Larson Family Investment Trust bought $94,018 worth of shares (87,500 units at $1.07), increasing direct ownership by 3% to 3,557,500 units (SEC Form 4)

    4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)

    4/15/25 2:02:44 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RMTI
    Financials

    Live finance-specific insights

    View All

    Rockwell Medical Announces Third Quarter 2025 Results

    Net sales for the third quarter 2025 were $15.9 million. Company reiterates 2025 guidance for net sales to be between $65 million and $70 million. Achieved profitability on an Adjusted EBITDA basis for the third quarter 2025. Increased cash position to $23.7 million at September 30, 2025. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three and nine months ended September 30, 2025. "During the third quarter, we continued to right-size our organization to enhance ope

    11/12/25 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rockwell Medical to Release Third Quarter 2025 Results on Wednesday, November 12, 2025

    Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the third quarter ended September 30, 2025 on Wednesday, November 12, 2025. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Wednesday, November 12, 2025 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMe

    10/15/25 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rockwell Medical Announces Second Quarter 2025 Results

    Generated $1.8 million in cash flow from operations for the second quarter of 2025. Reported gross margin of 16% for the second quarter of 2025, in line with 2025 guidance. Increased cash position at June 30, 2025 to $18.4 million. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three and six months ended June 30, 2025. "During the second quarter of 2025, we successfully managed through the transition of our largest customer away from Rockwell Medical and now find ou

    8/14/25 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RMTI
    Leadership Updates

    Live Leadership Updates

    View All

    Rockwell Medical Appoints Joe Dawson to the Company's Board of Directors

    Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joe Dawson to its board of directors. Additionally, Andrea Heslin Smiley has resigned from the Company's board of directors to pursue other endeavors. "We are pleased to welcome Joe to Rockwell Medical's board of directors. Joe is a seasoned executive who has extensive operational experience, a strong network in the renal care space, and deep domain expertise in building and scaling commercial organizations," said Robert S. Radie, Chairman of t

    11/18/25 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rockwell Medical Names Rashad Brown Vice President, Manufacturing and Supply Chain

    Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that Rashad Brown has joined the Company as Vice President, Manufacturing and Supply Chain. Mr. Brown brings more than two decades of leadership experience in manufacturing operations, procurement, warehouse management, and supply chain optimization within regulated healthcare manufacturing environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111461038/en/Rashad Brown - Vice President, Manufacturing

    11/11/25 6:00:00 AM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Universal Display Corporation Announces the Appointment of New Board Members

    Universal Display Corporation (NASDAQ:OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced that Dr. Nigel Brown and Dr. Joan Lau have joined the Company's Board of Directors, effective March 4, 2024. The addition of these new directors expands UDC's Board to ten members. "I am pleased to welcome Nigel and Joan to the Board," said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation and a member of the Board. "Nigel adds a wealth of business innovation, technical knowledge and corporate strategic planning expertise to our Board. Joan brings over two decades of extensive scienti

    3/7/24 4:05:00 PM ET
    $BDN
    $NOTV
    $OLED
    Real Estate Investment Trusts
    Real Estate
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $RMTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Rockwell Medical Inc.

    SC 13G/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)

    11/14/24 5:17:40 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Rockwell Medical Inc. (Amendment)

    SC 13G/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)

    2/14/24 2:31:02 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Rockwell Medical Inc. (Amendment)

    SC 13D/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)

    9/6/23 4:49:44 PM ET
    $RMTI
    Biotechnology: Pharmaceutical Preparations
    Health Care